Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | BRD2 | P25440 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1205304 | 0.88 | GAA (0.43) | KMT2AMEN1ALDH1A1PLA2G2ASMN1; SMN2 | |
| SCHEMBL9701615 | 0.85 | KMT2A (0.59) | KMT2AMEN1CREBBPBRD4BRD2 | |
| SCHEMBL1189147 | 0.84 | PLA2G2A (0.40) | KMT2AMEN1PLA2G2AL3MBTL1LMNA | |
| SCHEMBL9525773 | 0.81 | KMT2A (0.54) | KMT2AMEN1CREBBPBRD4BRD2 | |
| SCHEMBL9525522 | 0.78 | CA5A (0.57) | KMT2AMEN1CREBBPBRD4BRD2 | |
| SCHEMBL20239499 | 0.78 | KMT2A (0.54) | KMT2AMEN1CREBBPBRD4BRD2 | |
| SCHEMBL9969397 | 0.78 | MAOB (0.57) | KMT2AMEN1ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL9702910 | 0.78 | PLA2G2A (0.56) | KMT2AMEN1CREBBPBRD4BRD2 | |
| SCHEMBL27803384 | 0.78 | PTGS2 (0.45) | PLA2G2AL3MBTL1LMNAMAPK1KDM4E | |
| SCHEMBL1190221 | 0.78 | CREBBP (0.47) | KMT2AMEN1CREBBPBRD4BRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2240486-B1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, THEIR MANUFACTURE AND THEIR APPLICATION AS MEDICINE | SANOFI SA (FR) | 2015-09-09 | — | — | EP | disclosed |
| EP-2240486-B1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, THEIR MANUFACTURE AND THEIR APPLICATION AS MEDICINE | SANOFI SA (FR) | 2015-09-09 | — | — | EP | disclosed |
| US-9079906-B2 | Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2015-07-14 | — | — | US | disclosed |
| US-9079906-B2 | Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2015-07-14 | — | — | US | disclosed |
| US-9079906-B2 | Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2015-07-14 | — | — | US | disclosed |
| US-8853206-B2 | Triazolium salts as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2014-10-07 | — | — | US | disclosed |
| US-8853206-B2 | Triazolium salts as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2014-10-07 | — | — | US | disclosed |
| US-8853206-B2 | Triazolium salts as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2014-10-07 | — | — | US | disclosed |
| US-20120208805-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| US-20120208805-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| US-20110034452-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| US-20110034452-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| US-20110034451-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| US-20110034451-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| EP-2240487-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | Sanofi-Aventis (FR) | 2010-10-20 | — | — | EP | disclosed |
| EP-2240486-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | Sanofi-Aventis (FR) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009097970-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009097971-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009097971-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009097970-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034451-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | F2R, F2RL3, F2RL1 | KMT2A 2751/4885MEN1 1179/4885CREBBP 4461/4885 |
| US-20120208805-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | F2R, F2RL3, F2RL1 | KMT2A 3872/4885MEN1 746/4885CREBBP 4766/4885 |
| US-20110034452-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | F2R, F2RL3, F2RL1 | KMT2A 3882/4885MEN1 735/4885CREBBP 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.